Skip to main content

Month: June 2023

Nebulizer Market Size to Surpass USD 1,275.1 Million by 2030, exhibiting a CAGR of 5.2%

As per the report by Fortune Business Insights, the global Nebulizer Market size is projected to reach USD 1,275.1 Million in 2030, at a CAGR of 5.2% during the forecast period, 2023-2030 Pune, India, June 29, 2023 (GLOBE NEWSWIRE) — According to Fortune Business Insights, global nebulizer market size was valued at USD 863.4 million in 2022 and projected to grow from USD 897.0 million in 2023 to USD 1,275.1 million by 2030, exhibiting a CAGR of 5.2% during the forecast period. Increasing respiratory disorders and robust demand for innovative respiratory drug delivery services are expected to elevate the market’s progress. Fortune Business Insights™ presents this information in its report titled “Nebulizer Market, 2023-2030.” Key Industry DevelopmentMarch 2021: PARI Pharma GmbH declared the authorization of its LAMIRA Nebulizer...

Continue reading

Linux Operating System Market Size to Surpass USD 66.28 Billion by 2030, exhibiting a CAGR of 20.1%

As per the report by Fortune Business Insights, the global Linux Operating System Market size is projected to reach USD 66.28 Billion by 2030, at a CAGR of 20.1% during the forecast period. Pune, India, June 29, 2023 (GLOBE NEWSWIRE) — According to Fortune Business Insights, global Linux operating system market size was valued at USD 15.52 billion in 2022 and is projected to grow from USD 18.34 billion in 2023 to USD 66.28 billion by 2030, exhibiting a CAGR of 20.1% during the forecast period. Increasing Adoption of Linux Operating System among Servers and Embedded Systems to Drive Market Growth. This information is provided by Fortune Business Insights™ in its research report titled “Linux Operating System Market Forecast, 2023-2030.” The market growth is primarily driven by rising internet penetration and increased data...

Continue reading

Pasithea Therapeutics Announces Completion of GMP Manufacturing for PAS-004

— Represents the final step before submission of Investigational New Drug (IND) application to FDA, expected in the second half of 2023 — PALO ALTO, Calif. and MIAMI, June 29, 2023 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (“CNS”) disorders, today announced it has successfully completed manufacturing of GMP-compliant Phase 1 clinical supplies of the active pharmaceutical ingredient (“API”) of its lead product candidate PAS-004, a next-generation macrocyclic MEK Inhibitor. GMP-compliant manufacturing of API was the final step needed to support the Investigational New Drug (“IND”) application that the Company expects to file with the U.S. Food...

Continue reading

BlueRush Inc. Announces Impressive 3rd Quarter Results, Highlighting Continued Growth and Innovation in Personalized Video Technology

TORONTO, June 29, 2023 (GLOBE NEWSWIRE) — BlueRush Inc. (“BlueRush” or the “Company“) ‎‎‎(TSXV:BTV; OTCQB:BTVRF), ‎a pioneering personalized video Software as a Service (“SaaS“) company, is excited to announce strong 3rd quarter results and continued focus on platform innovation. The Company’s innovative SaaS platform, fueled by its personalized video technology, continues to drive growth, delivering superior customer engagement for businesses of all sizes. Key financial highlights for the 3rd quarter include:29% increase in SaaS revenues, totaling $755,636 compared to $584,883 for the same period in fiscal 2022 SaaS revenue for the nine-month period ending April 30, 2023, experienced a significant growth of 32%, reaching $2,254,711, compared to $1,706,846 for the same period last year Operating...

Continue reading

Theratechnologies to Announce Second Quarter 2023 Financial Results and Provide Business Update

MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second quarter ended May 31, 2023, on Wednesday, July 12 at 8:30 a.m. EDT. The call will be hosted by Mr. Paul Lévesque, President and Chief Executive Officer. Mr. Lévesque will joined be other members of the management team, including Chief Financial Officer, Mr. Philippe Dubuc, Chief Medical Officer, Dr. Christian Marsolais and Global Commercial Officer, Mr. John Leasure, who will be available to answer questions from participants following prepared remarks. Participants are encouraged to join the call at least...

Continue reading

Reunion Neuroscience Reports Fiscal Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Common Shareholders to Receive Consideration of US$1.12 Per Share in Cash from the Arrangement Agreement with MPM BioImpact; Special Shareholder Meeting Scheduled July 12 Presented Encouraging Phase 1 Final Analysis at American Society of Clinical Psychopharmacology Annual Meeting TORONTO, June 29, 2023 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or the “Company”), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today reported fiscal results for the fourth quarter and year ended March 31, 2023 and provided a corporate update. Corporate Updates On June 1, 2023, Reunion announced that it has agreed to a take-private transaction from MPM BioImpact, a world-leading biotechnology investment...

Continue reading

Nano Dimension Announces Record Q1/2023 Results Revenue of $14.97 Million, 43% YoY Growth

Gross Margins increased to 44% (Adjusted: 47%) Best Quarter in the Company’s History 50% Organic Revenue Growth since Q3/2022 Company Plans to Continue its Share Buy-Back Program Conference Call to be Held Today at 9:00 a.m. EDT Waltham, Massachusetts, June 29, 2023 (GLOBE NEWSWIRE) —  Nano Dimension Ltd. (Nasdaq: NNDM, “Nano Dimension” or the “Company”), a leading supplier of Additively Manufactured Electronics (“AME”) and multi-dimensional polymer, metal & ceramic Additive Manufacturing (“AM”) 3D printers, today announced financial results for the first quarter ended March 31st, 2023. The Company also announced the intention to promptly continue its share buy-back program. Nano Dimension reported consolidated record revenues of $14.97 million for Q1/2023, an increase of:43% over Q1/202224% over Q4/2022Gross Margin...

Continue reading

The Simply Good Foods Company Reports Third Quarter Fiscal Year 2023 Financial Results and Reaffirms Full Fiscal Year 2023 Outlook

DENVER, June 29, 2023 (GLOBE NEWSWIRE) — The Simply Good Foods Company (Nasdaq: SMPL) (“Simply Good Foods,” or the “Company”), a developer, marketer and seller of branded nutritional foods and snacking products, today reported financial results for the thirteen and thirty-nine weeks ended May 27, 2023. Third Quarter Summary:(1)Net sales of $324.8 million versus $316.5 million Net income(2) of $35.4 million versus $38.8 million Earnings per diluted share (“EPS”)(2) of $0.35 versus $0.38 Adjusted Diluted EPS(3) of $0.44, the same as the year ago period Adjusted EBITDA(4) of $66.6 million versus $63.3 millionReaffirm Full Year Fiscal 2023 Outlook:Net sales expected to increase slightly greater than the Company’s long-term algorithm of 4-6%, including a headwind of almost 1 percentage point related to the frozen pizza licensing Adjusted...

Continue reading

MariMed Announces Second Quarter 2023 Earnings Date

NORWOOD, Mass., June 29, 2023 (GLOBE NEWSWIRE) — MariMed Inc. (“MariMed” or the “Company”), (CSE: MRMD), (OTCQX: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced it will report its second quarter 2023 financial results on August 2, 2023 after the markets close. Management will host a conference call on August 3, 2023 at 8:00 a.m. EST to discuss financial results. A webcast will be available and can be accessed via MariMed’s Investor Relations website at MariMed Q223 Earnings Webcast. A playback of the call will also be made available on MariMed’s Investor Relations website. About MariMedMariMed Inc., a multi-state cannabis operator, is dedicated to improving lives every day through its high-quality products, its actions, and its values. The Company develops, owns, and manages...

Continue reading

Clean Motion increases prices for the electric vehicle EVIG

Clean Motion is set to increase the prices of its solar-powered electric vehicle, EVIG. The new prices will take effect from July 1, 2023. The reason is an adjustment towards the market price of comparable competitors and the assessment is that the offer will continue to be very attractive. On average, prices will increase by 35%. Clean Motion launched the solar-powered vehicle EVIG for last-mile deliveries in cities in the fall of 2022. The development was completed in the spring of 2023 and production has started. With this, the company will raise the prices for new orders. The reason is an adjustment towards the market price of comparable competitors. On average, prices will increase by 35% and will take effect on July 1, 2023. “Even after the increase, EVIG is still very competitively priced and continues to hold its position...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.